Skip to main content
Premium Trial:

Request an Annual Quote

Agendia Cites Unfavorable Market Conditions in Postponing IPO

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Agendia today said it is postponing its planned initial public offering, citing unfavorable market conditions.

In a statement, the molecular diagnostics firm said that its planned offering coincides with an "extraordinarily volatile period in global capital markets resulting in high levels of uncertainty and volatility that do not meet the existing shareholders' and the company's desire to achieve a successful IPO with an orderly aftermarket."

Agendia CEO Bernhard Sixt added, "We are pleased by the response we have received from investors but current volatile and uncertain market conditions do not allow us to launch the transaction and achieve a smooth transition into the public markets." He added that the firm will "continue to increase the pace of commercial growth as a private company supported by our existing shareholders who are committed to the successful future growth of the company."

Based in Amsterdam, Agendia said two weeks ago it had filed for an IPO to sell shares on the NYSE Euronext. The firm had expected to begin trading on June 21 and planned to sell up to 4,587,156 new shares at a price of between €16.35 and €19.15 per share. At the mid-point of the range, the offering would have raised about €81.4 million ($116.4 million) before the exercise of an over-allotment option of up to 688,073 shares.

Agendia is the third 'omics firm to pull its IPO since the start of the year. Earlier, AutoGenomics and Atossa Genetics also withdrew their planned offerings.

The Scan

mRNA-Based Vaccine on the Way in China

China may soon have its own mRNA-based vaccine, according to Nature News.

Arranged Killing, Fraud Alleged by Prosecutors

The Wall Street Journal reports that prosecutors allege that the co-founder of a biotech arranged to have a business associate who threatened to expose him as a fraud killed.

Whirlwind Decade of CRISPR

The New York Times looks back at the 10 years since the University of California, Berkeley's Jennifer Doudna and her colleagues published their CRISPR paper.

PNAS Papers on Blue Cone Monochromacy Structural Variants, HIV-1 Mutant, T-ALL

In PNAS this week: structural variants linked to blue cone monochromacy, HIV-1 variants affecting the matrix protein p17, and more.